GlassScriptPhysician profile
Matthew Vasquez
NPI 1144780651
$892.70
in general payments reported to CMS, 2019-2025
15 companies · $761 in 2025
The $761 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $91.06 · 2024: $40.80 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $185.95 | 2025 | |
| Biogen, INC. | $165.30 | 2025 | Vumerity, Tysabri |
| Takeda Pharmaceuticals U.S.A., INC. | $91.06 | 2023 | |
| Celgene Corporation | $90.99 | 2025 | Zeposia |
| Emd Serono, INC. | $78.74 | 2025 | Mavenclad |
| Pfizer INC. | $69.98 | 2025 | |
| Ge Healthcare | $41.65 | 2025 | |
| Tg Therapeutics, INC. | $32.00 | 2025 | |
| Inspire Medical Systems, INC. | $21.66 | 2025 | Inspire |
| Lundbeck LLC | $21.00 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $20.83 | 2024 | Ingrezza |
| Ucb, INC. | $19.97 | 2024 | Briviact |
| Otsuka America Pharmaceutical, INC. | $18.87 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $18.50 | 2025 | Nuplazid |
| Averitas Pharma INC. | $16.20 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.